Serologic assay for silent brain ischemia

A method for managing a risk of stroke in a subject in need thereof, the method comprising:

• administering or having administered one or more of aspirin therapy, blood pressure therapy, body weight management, and a program of diet and exercise to the subject at risk of stroke,
• wherein the subject was identified as at risk of stroke according to an assigned score being greater than a threshold score, the assigned score representing amounts of a plurality of biomarkers from a sample obtained from the subject compared to corresponding amounts of the plurality of biomarkers in a normal control sample,
• wherein the plurality of biomarkers comprises five or more of IGFBP2, ITBG3, CXCL5, CXCL6, TNFa, IL-18, IL-6, Fibrinogen, MCP-1, BDNF, GDF-15, ST2, FGF-23, SRAGE, MPO, and LpPLA2,
• wherein the sample obtained from the subject is one of a cerebrospinal fluid sample, a urine sample, or a blood sample.

A method for managing a risk of stroke in a subject, the method comprising:

• (a) obtaining measured amounts of a plurality of biomarkers comprising five or more of IGFBP2, ITBG3, CXCL5, CXCL6, TNFa, IL-18, IL-6, Fibrinogen, MCP-1, BDNF, GDF-15, ST2, FGF-23, SRAGE, MPO, and LpPLA2,
• (b) assigning a score representing measured amounts of the plurality of biomarkers compared to corresponding amounts of the plurality of biomarkers in a normal control;
• and
• (c) administering or having administered treatment to the subject at risk of stroke if the score is greater than a threshold value, wherein the treatment is selected from aspirin therapy, blood pressure therapy, body weight management, and/or a program of diet and exercise,
• wherein the sample is a cerebrospinal fluid sample, a urine sample, or a blood sample.